Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT06598800 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06598800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06598800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Recruiting
Start date
October 18, 2024
Completion date
September 30, 2028
Enrollment
153 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor